Tempus AI Inc. (NASDAQ: TEM) announced the U.S. Food and Drug Administration has approved a tumor-only indication for its xT ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE